Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.

Inclusion Criteria:

• Males or females, ages 18 to 85 (inclusive) at the time of screening.
• Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
• No clinically significant abnormalities in hematology, blood chemistry, or urinalysislaboratory tests at screening.
• Must agree not to enroll in another study of an investigational agent prior tocompletion of the study.
• Normal oral temperature, pulse rate no greater than 100 beats per minute (sinusrhythm) and controlled blood pressure (in the case of hypertensives under treatment,below 140/90 mmHg).
• Subjects must be able to understand the requirements of the study and must beaccessible and willing to comply with the study procedures even under lock downconditions.
• Ability to provide informed consent -

Exclusion Criteria:

• History of severe local or systemic reactions to any vaccination or a history ofsevere allergic reactions or known allergy to the components of the vaccine, includingallergy to rice.
• Receipt of investigational product (except of confirmed placebo in IIBR20-001 study)up to 30 days prior to screening or ongoing participation in another clinical trial (except of IIBR20-001 trial).
• Receipt of licensed vaccines within 14 days of planned study immunization and any AE'spossibly related to licensed vaccine immunization at Day 0.
• Inability to observe possible local reactions at the injection sites due to a physicalcondition or permanent body art.
• Known hemoglobinopathy or coagulation abnormality (subjects treated by anticoagulationor anti platelets are not excluded).
• New onset of fever >37.8ºC AND [cough OR shortness of breath OR anosmia/ageusia], orany other inter current illness within 14 days prior to screening
• Factors that increase risk to the subject to severe disease per CDC guidance includingthe following risk factors (in any case of ambiguous grading, decision will be madeper investigator's best clinical judgement): Cancer [ongoing malignancy or recentlydiagnosed malignancy in the last five years, not including non-melanotic skin cancer],Chronic Kidney Disease (eGFR<60 mL/min/1.73 m^2), liver disease (ALT or AST) > 1.5 ×ULN; or alkaline phosphatase and direct bilirubin > ULN (total bilirubin may be up to 2 × ULN as long as direct bilirubin is equal to or below the ULN); or PT INR > 1.25),COPD; Immunocompromised state from solid organ transplant; Obesity (BMI≥30kg/m2);Serious heart conditions, such as heart failure, coronary artery disease, orcardiomyopathies; Sickle cell disease; Type 1/2 diabetes mellitus (HbA1C>8.0%, permedical history questioning or records) ); Asthma; Cerebrovascular disease; Cysticfibrosis, uncontrolled hypertension that does not respond to therapy, Pulmonaryfibrosis, Thalassemia. Anticipating the need for immunosuppressive treatment within the next 6 months. Clinicallysignificant (by means of potentially risking the subject or that would be potentiallydetrimental to the results of the study) medical condition, physical examination findings,clinically significant abnormal laboratory results, or past medical history with clinicallysignificant implications for current health or for severe COVID-19, per the investigator. Any progressive or severe neurologic condition/disorder, dementia, seizure disorder, orhistory of Guillian-Barré syndrome.
• Known or suspected impairment of the immune system including rheumatic, connectivetissue or vascular disease of autoimmune origin
• Clinically significant abnormal CBC results in WBC, hemoglobin, hematocrit, orplatelets.
• Clinically significant abnormal urinalysis: RBC, protein, or glucose only.
• Positive serology for: hepatitis B surface antigen, hepatitis C, HIV.
• Known or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle EastRespiratory Syndrome (MERS)-CoV..
• Received any prior vaccine against a coronavirus.
• Receipt of blood/plasma products or immunoglobulin, from within 60 days before studyintervention administration or planned receipt throughout the study.
• Immunosuppressive medications received within 90 days before screening. (Not including [1] corticosteroid nasal spray for allergic rhinitis; [2] topical corticosteroids formild, uncomplicated dermatitis; or [3] oral/parenteral corticosteroids given fornon-chronic conditions not expected to recur [length of therapy 10 days or less withcompletion at least 30 days prior to vaccination].)
• History of alcohol or drug abuse per clinical judgement within 5 years prior to studyvaccination (excluding cannabis)
• Participants who, in the judgment of the investigator, will be unlikely to comply withthe requirements of this protocol.
• Any other significant finding that in the opinion of the investigator would increasethe risk of the individual having an adverse outcome from participating in this study.